South Korea
· Delayed Price · Currency is KRW Meta Biomed Statistics
Total Valuation
Meta Biomed has a market cap or net worth of KRW 137.48 billion. The enterprise value is 139.38 billion.
| Market Cap | 137.48B |
| Enterprise Value | 139.38B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Meta Biomed has 27.06 million shares outstanding. The number of shares has decreased by -32.66% in one year.
| Current Share Class | 27.06M |
| Shares Outstanding | 27.06M |
| Shares Change (YoY) | -32.66% |
| Shares Change (QoQ) | +17.81% |
| Owned by Insiders (%) | 21.57% |
| Owned by Institutions (%) | 5.78% |
| Float | 21.23M |
Valuation Ratios
The trailing PE ratio is 8.25 and the forward PE ratio is 6.22.
| PE Ratio | 8.25 |
| Forward PE | 6.22 |
| PS Ratio | 1.38 |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | 36.08 |
| P/OCF Ratio | 7.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.76, with an EV/FCF ratio of 36.58.
| EV / Earnings | 7.59 |
| EV / Sales | 1.40 |
| EV / EBITDA | 4.76 |
| EV / EBIT | 5.84 |
| EV / FCF | 36.58 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.36.
| Current Ratio | 1.55 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | 1.53 |
| Debt / FCF | 11.52 |
| Interest Coverage | 6.95 |
Financial Efficiency
Return on equity (ROE) is 17.64% and return on invested capital (ROIC) is 9.45%.
| Return on Equity (ROE) | 17.64% |
| Return on Assets (ROA) | 8.33% |
| Return on Invested Capital (ROIC) | 9.45% |
| Return on Capital Employed (ROCE) | 18.91% |
| Revenue Per Employee | 320.79M |
| Profits Per Employee | 59.08M |
| Employee Count | 311 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.41 |
Taxes
In the past 12 months, Meta Biomed has paid 3.48 billion in taxes.
| Income Tax | 3.48B |
| Effective Tax Rate | 15.98% |
Stock Price Statistics
The stock price has increased by +48.11% in the last 52 weeks. The beta is 0.63, so Meta Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +48.11% |
| 50-Day Moving Average | 5,676.70 |
| 200-Day Moving Average | 5,332.08 |
| Relative Strength Index (RSI) | 40.73 |
| Average Volume (20 Days) | 401,923 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Meta Biomed had revenue of KRW 99.77 billion and earned 18.38 billion in profits. Earnings per share was 615.37.
| Revenue | 99.77B |
| Gross Profit | 54.49B |
| Operating Income | 23.33B |
| Pretax Income | 21.75B |
| Net Income | 18.38B |
| EBITDA | 28.75B |
| EBIT | 23.33B |
| Earnings Per Share (EPS) | 615.37 |
Balance Sheet
The company has 42.67 billion in cash and 43.89 billion in debt, giving a net cash position of -1.22 billion or -45.20 per share.
| Cash & Cash Equivalents | 42.67B |
| Total Debt | 43.89B |
| Net Cash | -1.22B |
| Net Cash Per Share | -45.20 |
| Equity (Book Value) | 121.24B |
| Book Value Per Share | 4,496.49 |
| Working Capital | 31.34B |
Cash Flow
In the last 12 months, operating cash flow was 17.33 billion and capital expenditures -13.52 billion, giving a free cash flow of 3.81 billion.
| Operating Cash Flow | 17.33B |
| Capital Expenditures | -13.52B |
| Free Cash Flow | 3.81B |
| FCF Per Share | 140.79 |
Margins
Gross margin is 54.62%, with operating and profit margins of 23.38% and 18.42%.
| Gross Margin | 54.62% |
| Operating Margin | 23.38% |
| Pretax Margin | 21.80% |
| Profit Margin | 18.42% |
| EBITDA Margin | 28.82% |
| EBIT Margin | 23.38% |
| FCF Margin | 3.82% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.59%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.59% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 1.80% |
| Buyback Yield | 32.66% |
| Shareholder Yield | 33.26% |
| Earnings Yield | 13.37% |
| FCF Yield | 2.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 23, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Meta Biomed has an Altman Z-Score of 2.8 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 6 |